AHA/ACC/HFSA 2022 Heart Failure Guidelines: U.S. vs. Global Practice

Abstract

The management of heart failure (HF) has been fundamentally redefined by successive international guidelines. This article provides a comparative review of the 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America (AHA/ACC/HFSA) and the 2021 European Society of Cardiology (ESC) guidelines, two seminal documents governing global HF practice. 

While both converge on the core Guideline-Directed Medical Therapy (GDMT) for Heart Failure with Reduced Ejection Fraction (HFrEF)—emphasizing the four pillars, including SGLT2 inhibitors—key differences remain in disease staging, classification, and the strength of recommendations for certain therapeutic and device interventions. The AHA/ACC/HFSA 2022 guideline uniquely focuses on the progression from “At Risk for HF” (Stage A) to advanced disease (Stage D) and incorporates social determinants of health. 

Understanding these distinctions is critical for cardiologists, internists, and allied health professionals to harmonize global evidence into localized, optimal patient care strategies.

Introduction: A New Global Standard for Heart Failure Management

Heart failure (HF) remains a global public health crisis, characterized by high morbidity, frequent hospitalizations, and elevated mortality rates. It affects over 64 million people worldwide and represents a major burden on healthcare systems. 

The rapid evolution of evidence, particularly concerning novel pharmacologic agents such as the Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors, necessitates periodic updates to clinical practice standards. 

The 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America (AHA/ACC/HFSA) guidelines and the 2021 European Society of Cardiology (ESC) guidelines serve as the two preeminent, evidence-based frameworks for the diagnosis and management of HF. 

While both documents reflect a consensus on the paramount importance of Guideline-Directed Medical Therapy (GDMT), subtle yet significant differences exist in their methodological approach, terminology, and recommendation strength. 

This article compares and contrasts these two foundational documents to provide practitioners with the necessary context for interpreting global HF management strategies and integrating the highest quality evidence into local clinical decision-making.

Classification and Staging: The Foundational Differences (Diagnosis)

While both the AHA/ACC/HFSA and ESC guidelines classify heart failure (HF) based on Left Ventricular Ejection Fraction (LVEF), the fundamental approach to disease progression—staging—represents a key divergence. 

The AHA/ACC/HFSA system maintains the established A-B-C-D staging framework, which emphasizes the continuum of disease from risk factors to end-stage disease, while the ESC guidelines primarily focus on the symptomatic and functional classification of patients who have already developed structural or functional cardiac abnormalities.

Stages of Heart Failure: The AHA/ACC/HFSA Continuum

The AHA/ACC/HFSA 2022 guideline reinforces its prognostic staging system, which is centered on preventing the progression of HF. The guideline notably refined Stage B to incorporate the new category of “Pre-Heart Failure.”

• Stage A (At Risk for HF): Patients with major risk factors (e.g., hypertension, diabetes, obesity) but no structural or functional heart disease and normal natriuretic peptide levels.
  
  
• Stage B (Pre-Heart Failure): Patients with structural heart disease (e.g., left ventricular hypertrophy, regional wall motion abnormalities) or evidence of increased filling pressures (e.g., elevated natriuretic peptides) but who are asymptomatic. This stage is crucial as it emphasizes early intervention.
  
  
• Stage C (Symptomatic HF): Patients with current or prior HF symptoms and underlying structural heart disease.
  
  
• Stage D (Advanced HF): Patients with refractory symptoms despite maximal guideline-directed medical therapy (GDMT).
  
  

LVEF Phenotypes: Shared and Distinct Classifications

Both international bodies utilize LVEF to categorize HF patients for therapeutic guidance, leading to a high degree of concordance in pharmacologic recommendations.

The HFimpEF classification is introduced in both guidelines to identify a unique therapeutic group, emphasizing the need to continue GDMT even after LVEF recovery, based on evidence suggesting risk of relapse upon therapy withdrawal. 

While the numerical cutoffs are identical, the ESC framework integrates the symptomatic New York Heart Association (NYHA) classification more prominently into its overall diagnostic algorithms compared to the staging-centric U.S. approach.

Pharmacologic Management: Key Therapeutic Commonalities and Divergences (Treatment)

The core principle of both guidelines is the early and simultaneous initiation of Guideline-Directed Medical Therapy (GDMT). Both documents emphasize a rapid, sequential titration of foundational drug classes, largely driven by the landmark findings of contemporary randomized controlled trials (RCTs), particularly the integration of SGLT2 inhibitors.

Management of Heart Failure with Reduced Ejection Fraction (HFrEF)

The consensus on HFrEF (LVEF ≤ 40%) management is remarkably strong, solidifying the four pillars of GDMT, often termed “quadruple therapy,” as a Class I, Level A recommendation in both frameworks.

The Quadruple Therapy Cornerstone

The four essential drug classes for HFrEF patients are:

1. Angiotensin Receptor-Neprilysin Inhibitors (ARNi) or Angiotensin-Converting Enzyme Inhibitors (ACEi) or Angiotensin Receptor Blockers (ARB).
   
   
2. Beta-Blockers (BB).
   
   
3. Mineralocorticoid Receptor Antagonists (MRA).
   
   
4. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i), specifically dapagliflozin or empagliflozin.
   
   

Both the AHA/ACC/HFSA 2022 and ESC 2021 guidelines grant SGLT2 inhibitors a Class I recommendation for all HFrEF patients, reflecting the irrefutable evidence from trials such as DAPA-HF and EMPEROR-Reduced, demonstrating improved cardiovascular outcomes and reduced hospitalization irrespective of diabetes status.

RAS Inhibition Initiation Strategy

A subtle but important difference exists in the hierarchy and preference for inhibitors of the Renin-Angiotensin System (RAS):

• AHA/ACC/HFSA 2022: Explicitly states that ARNi is preferred over ACEi/ARB to optimize outcomes in eligible patients with HFrEF, making a strong case for its use as a first-line therapeutic choice.
  
  
• ESC 2021: While ARNi is highly recommended, the ESC framework allows for a more sequential approach where an ACEi/ARB may be started first and then switched to an ARNi if the patient remains symptomatic. The initial ESC guidance structured the four pillars as co-dependent, whereas the U.S. guideline prioritizes the ARNi benefit more directly.
  
  

Management of Heart Failure with Mildly Reduced/Preserved Ejection Fraction (HFmrEF/HFpEF)

The management of patients with LVEF ≥ 41% saw the most significant updates, largely driven by the success of SGLT2 inhibitors.

SGLT2i Across the Spectrum

The evidence supporting SGLT2i (dapagliflozin/empagliflozin) benefit extends across the LVEF spectrum:

• AHA/ACC/HFSA 2022: Provides a Class 2a recommendation for SGLT2i in patients with HFmrEF (LVEF 41%–49%) and a Class 2a recommendation in select patients with HFpEF (LVEF ≥ 50%).
  
  
• ESC 2021: Also provides a Class I, Level A recommendation for SGLT2i (dapagliflozin/empagliflozin) for patients with HFmrEF and a Class I, Level A recommendation for patients with HFpEF, establishing SGLT2i as the only drug class receiving a Class I recommendation for these phenotypes in the European framework.
  
  

This distinction is notable: the ESC gives SGLT2i a Class I recommendation for HFpEF, while the AHA/ACC/HFSA assigns a Class 2a. Both recognize the importance of SGLT2i in these groups (based on EMPEROR-Preserved and DELIVER trials), but the ESC applies the highest level of recommendation, reflecting a more decisive endorsement of the evidence.

Additional Pharmacotherapy

Both guidelines support the use of other agents in HFpEF and HFmrEF based on comorbidities:

• Mineralocorticoid Receptor Antagonists (MRAs): Both guidelines recommend MRAs for select patients with HFpEF/HFmrEF, particularly those with volume overload or persistent symptoms.
  
  
• ARNi and ARBs: Recommended in patients with HFmrEF (Class 2a in ESC; Class 2b/2a in AHA/ACC/HFSA) but have a less robust role in HFpEF in both guidelines, mainly addressing associated hypertension. The benefit is more pronounced in the lower LVEF ranges of the HFpEF/HFmrEF spectrum.
  
  

Devices and Interventions: Variations in Recommendation Strength

While pharmacologic GDMT represents the core of heart failure (HF) management, device therapy and specific interventions offer crucial support for patient outcomes, particularly in advanced stages. Both guidelines address the use of Implantable Cardioverter-Defibrillators (ICD), Cardiac Resynchronization Therapy (CRT), and interventions for valvular disease, though with subtle differences in the strength of evidence and patient selection criteria.

Implantable Cardioverter-Defibrillators (ICD)

The use of primary prevention ICDs in patients with non-ischemic cardiomyopathy (NICM) following appropriate GDMT optimization is a significant area of comparison.

Primary Prevention in Nonischemic Cardiomyopathy

• AHA/ACC/HFSA 2022: The U.S. guideline provides a strong Class I, Level A recommendation for primary prevention ICD implantation in patients with NICM, LVEF ≤ 35%, and NYHA Class II or III symptoms who are expected to survive with good functional status for >1 year, despite optimized GDMT.
  
  
• ESC 2021: The European guideline issues a slightly more conditional Class 2a recommendation for the same population. The ESC framework often reserves the highest Class I recommendation for patients with ischemic etiology, reflecting a more cautious approach to device implantation in NICM.
  
  

Interventional Therapies and Device Management

Cardiac Resynchronization Therapy (CRT)

Both guidelines maintain a strong Class I recommendation for CRT in symptomatic patients (NYHA Class II–IV) with HFrEF and severe LVEF reduction who exhibit a wide QRS duration (≥150 milliseconds) and Left Bundle Branch Block (LBBB) morphology.

Mitral Regurgitation Interventions

The guidelines have converged following key trial data (e.g., COAPT) regarding transcatheter edge-to-edge repair (TEER) for severe secondary (functional) mitral regurgitation (SMR) in selected symptomatic HF patients on optimal GDMT. Both the AHA/ACC/HFSA and the ESC provide a Class 2a recommendation for TEER in highly selected patients who meet specific clinical and anatomical criteria.

Special Considerations and Ethical Focus (Outcomes & Compliance)

Beyond core diagnostics and standard pharmacotherapy, modern heart failure (HF) guidelines increasingly address the complexities of patient care, including managing specific comorbidities and acknowledging non-clinical factors that influence outcomes. This is where the 2022 AHA/ACC/HFSA guideline demonstrates a unique focus on holistic patient management.

Social Determinants of Health (SDOH) and Value Statements

A notable distinguishing feature of the U.S. guideline is its explicit inclusion of recommendations addressing the non-traditional aspects of care that impact compliance and prognosis.

• The AHA/ACC/HFSA 2022 guideline includes Class 1 recommendations urging clinicians to assess and address Social Determinants of Health (SDOH), such as health literacy, access to care, and economic factors, as these significantly influence the uptake and adherence to GDMT.
  
  
• The U.S. guideline also contains a specific section addressing the cost-effectiveness and value of therapies, reflecting a practical approach to healthcare resource allocation.
  
  

Amyloidosis and Comorbidities

• Both the AHA/ACC/HFSA and the ESC guidelines give strong recommendations for the use of Tafamidis for patients with symptomatic Transthyretin Cardiac Amyloidosis (ATTR-CA).
  
  
• Both guidelines emphasize the importance of managing iron deficiency in HFrEF patients, with a Class 2a recommendation for the use of intravenous iron (e.g., ferric carboxymaltose), irrespective of anemia status, to improve functional capacity and quality of life.
  
  

Practice Highlights: Bridging the Guidelines

The key for practicing clinicians is to reconcile the differences between the AHA/ACC/HFSA 2022 and ESC 2021 guidelines to deliver the highest standard of care, regardless of geographic location. Both documents provide robust, evidence-based recommendations; the primary divergence lies in the emphasis, staging, and degree of therapeutic endorsement for newer agents across the LVEF spectrum.

Core GDMT for HFrEF: A Comparative Snapshot

The following table summarizes the foundational pharmacological pillars for Heart Failure with Reduced Ejection Fraction (HFrEF) and highlights the subtle differences in recommendation strength and preference.

Bridging the HFpEF/HFmrEF Divide

The most significant consensus for HFpEF and HFmrEF is the benefit of SGLT2 inhibitors. While the ESC grants SGLT2i a Class I recommendation for HFpEF, the AHA/ACC/HFSA uses a Class 2a. Clinicians should recognize the strong evidence base (DELIVER, EMPEROR-Preserved trials) supporting the broad use of SGLT2 inhibitors across the LVEF spectrum.

Clinical Practice Summary: Key Takeaways for Global Care

The 2022 AHA/ACC/HFSA and 2021 ESC guidelines represent a unified, evidence-based approach to heart failure (HF) management, largely driven by the universal acceptance of SGLT2 inhibitors as foundational therapy across the entire LVEF spectrum. The central message remains consistent: prompt diagnosis, initiation of Guideline-Directed Medical Therapy (GDMT), and aggressive titration to target doses are paramount to reducing mortality and hospitalizations.

Key Takeaways for Clinical Practice

1. Universal Quadruple Therapy for HFrEF: The four pillars—ARNi/ACEi/ARB, Beta-Blockers, MRA, and SGLT2i—are now mandatory Class I therapies for symptomatic HFrEF (LVEF ≤ 40%).
   
   
2. SGLT2 Inhibitors for All Phenotypes: SGLT2i should be a primary consideration for nearly all HF patients (HFrEF, HFmrEF, and HFpEF), bridging the gap between the U.S. and European recommendations.
   
   
3. Prioritizing Risk and Prevention: The AHA/ACC/HFSA staging system (A–D) provides a crucial framework for primary prevention, urging physicians to treat risk factors (Stage A) and subclinical disease (Stage B) aggressively.
   
   
4. Navigating Device Differences: When considering primary prevention ICDs for non-ischemic cardiomyopathy, the stronger Class I endorsement in the U.S. guideline must be reconciled with the more conditional Class 2a ESC stance during Heart Team discussions.
   
   
5. Holistic Care Beyond Pharmacology: Intervening on Social Determinants of Health (SDOH) is increasingly recognized as a Class I recommendation in the U.S. guideline to ensure optimal compliance and equitable care delivery.